Anteroposterior gradients in cerebral glucose use in schizophrenia and affective disorders
- PMID: 6334502
- DOI: 10.1001/archpsyc.1984.01790230045007
Anteroposterior gradients in cerebral glucose use in schizophrenia and affective disorders
Abstract
Local cerebral uptake of deoxyglucose labeled with fluorine 18 was measured by positron emission tomography in 16 patients with schizophrenia and 11 patients with affective disorder. Patients received no medication a minimum of 14 days and an average of 39.8 days. The subjects were administered the deoxyglucose 18F just before receiving a 34-minute 1/s series of unpleasant electrical stimuli to the right forearm while resting with eyes closed in a darkened, acoustically attenuated psychophysiologic testing chamber. Following monitored stimulation in the controlled environment, subjects were scanned and images converted to values of glucose use in micromoles per 100 g per minute according to Sokoloff's model. Data were analyzed with a four-way analysis of variance (ANOVA) with independent groups (normals, schizophrenics, and affectives) and repeated measures for slice level (supraventricular, midventricular, and infraventricular), hemisphere (right, left), and anteroposterior position (four sectors). Both normal subjects and patients showed a significant anteroposterior gradient in glucose use with highest values in the frontmost sector. Patients both with schizophrenia and with affective illness showed less of an anteroposterior gradient especially at superior levels, which was statistically confirmed by ANOVA. Absolute glucose levels in patients, which were actually higher in posterior regions rather than lower in frontal regions, were the largest contributors to the effect. Neither group differences in whole brain glucose use nor left-right asymmetries reached statistical significance. These results are consistent with our earlier reports of a relative hypofrontal function in schizophrenia compared with controls. This report extends this finding to affective illness, sharing a lack of diagnostic specificity with many biologic measures.
Similar articles
-
Positron emission tomographic image measurement in schizophrenia and affective disorders.Ann Neurol. 1984;15 Suppl:S157-65. doi: 10.1002/ana.410150730. Ann Neurol. 1984. PMID: 6611116
-
Cerebral glucography with positron tomography. Use in normal subjects and in patients with schizophrenia.Arch Gen Psychiatry. 1982 Mar;39(3):251-9. doi: 10.1001/archpsyc.1982.04290030001001. Arch Gen Psychiatry. 1982. PMID: 6978119
-
Cerebral metabolic consequences of electrical cutaneous stimulation in normal individuals.Hum Neurobiol. 1983;2(1):35-8. Hum Neurobiol. 1983. PMID: 6603452
-
[No hypofrontality in schizophrenia demonstrated by positron emission tomography].Acta Psychiatr Belg. 1992 Sep-Oct;92(5):261-78. Acta Psychiatr Belg. 1992. PMID: 1345405 Review. French.
-
Positron emission tomography.Psychiatr Clin North Am. 1986 Mar;9(1):63-79. Psychiatr Clin North Am. 1986. PMID: 3515332 Review.
Cited by
-
Proteomic enrichment analysis of psychotic and affective disorders reveals common signatures in presynaptic glutamatergic signaling and energy metabolism.Int J Neuropsychopharmacol. 2014 Oct 31;18(2):pyu019. doi: 10.1093/ijnp/pyu019. Int J Neuropsychopharmacol. 2014. PMID: 25609598 Free PMC article.
-
Increased sensitivity to the sensorimotor gating-disruptive effects of apomorphine after lesions of medial prefrontal cortex or ventral hippocampus in adult rats.Psychopharmacology (Berl). 1995 Nov;122(1):27-34. doi: 10.1007/BF02246438. Psychopharmacology (Berl). 1995. PMID: 8711061
-
Effects of amphetamine on local cerebral metabolism in normal and schizophrenic subjects as determined by positron emission tomography.Psychopharmacology (Berl). 1987;92(2):241-6. doi: 10.1007/BF00177923. Psychopharmacology (Berl). 1987. PMID: 3110848 Clinical Trial.
-
Assessment of changes in regional cerebral blood flow in patients with major depression using the 99mTc-HMPAO single photon emission tomography method.Eur J Nucl Med. 1992;19(12):1038-43. doi: 10.1007/BF00180865. Eur J Nucl Med. 1992. PMID: 1464356
-
Functional magnetic resonance imaging in schizophrenia: current evidence, methodological advances, limitations and future directions.World Psychiatry. 2024 Feb;23(1):26-51. doi: 10.1002/wps.21159. World Psychiatry. 2024. PMID: 38214624 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical